share_log

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

Ocugen将于美国东部时间5月14日星期二上午8点30分举行电话会议,讨论业务更新和2024年第一季度财务业绩
Ocugen ·  05/03 12:00

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 14, 2024.

宾夕法尼亚州马尔文,2024年5月3日(GLOBE NEWSWIRE)——专注于发现、开发和商业化新型基因和细胞疗法及疫苗的生物技术公司Ocugen公司(Ocugen或公司)(纳斯达克股票代码:OCGN)今天宣布,它将举办电话会议和网络直播,讨论公司2024年第一季度的财务业绩,并于美国东部时间周二上午8点30分提供业务最新情况,2024 年 5 月 14 日。

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Ocugen将在同一天发布盘前收益公告。邀请与会者使用以下详细信息参加电话会议:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 8699924
Webcast: Available on the events section of the Ocugen investor site

拨入号码:(800) 美国来电者为 715-9871,国际来电者为 (646) 307-1963
会议 ID:8699924
网络直播:可在 事件 Ocugen 的部分 投资者网站

A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site.

电话会议和存档网络直播的重播将在活动结束后的大约45天内在Ocugen上播出 投资者网站

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient's lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

关于 Ocugen, Inc.
Ocugen, Inc. 是一家生物技术公司,专注于发现、开发和商业化能够改善健康并为全球患者带来希望的新型基因和细胞疗法和疫苗。我们正在通过勇敢的创新对患者的生活产生影响——开辟新的科学道路,利用我们独特的智力和人力资本。我们的突破性修饰基因疗法平台有可能用单一产品治疗多种视网膜疾病,我们正在推进传染病研究,以支持公共卫生和骨科疾病,以满足未得到满足的医疗需求。在以下网址了解更多 www.ocugen.com 然后关注我们 X领英

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

关于前瞻性陈述的警示说明
本新闻稿包含1995年《私人证券诉讼改革法》所指的前瞻性陈述,这些陈述存在风险和不确定性。在某些情况下,我们可能会使用 “预测”、“相信”、“潜力”、“提议”、“继续”、“估计”、“预期”、“期望”、“计划”、“打算”、“可能”、“可能”、“可能”、“可能”、“将”、“应该” 或其他传达未来事件或结果不确定性的词语来识别这些前瞻性陈述。此类陈述受许多重要因素、风险和不确定性的影响,这些因素可能导致实际事件或结果与我们当前的预期存在重大差异。我们在向美国证券交易委员会(SEC)提交的定期文件中更全面地描述了这些以及其他风险和不确定性,包括我们在向美国证券交易委员会提交的季度和年度报告中标题为 “风险因素” 的部分中描述的风险因素。我们在本新闻稿中作出的任何前瞻性陈述仅代表截至本新闻稿发布之日。除非法律要求,否则在本新闻稿发布之日之后,我们没有义务更新本新闻稿中包含的前瞻性陈述,无论是由于新信息、未来事件还是其他原因。

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com

联系人:
蒂芙尼汉密尔顿
传播主管
Tiffany.Hamilton@ocugen.com

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发